Celcuity, a biotech company, receives its first U.S. FDA approval related to a breast cancer product, according to Investing.com. The approval marks a regulatory milestone for the company’s breast cancer program and represents the first FDA greenlight in its category. At the same time, Investing.com reports that Celcuity’s shares fall, attributing the decline to investor concerns that the company’s broader breast cancer drug launch timeline is delayed. The coverage contrasts the positive impact of the FDA approval with the market reaction to the prospect of later commercial rollout. Taken together, the reports indicate that the FDA decision is a significant step toward commercialization, but investors weigh it against expected timing issues for additional launches and related development milestones. The articles do not provide further detail here on the specific indication, labeling scope, or immediate commercial plans beyond the fact of FDA approval and the reported share price movement tied to launch timing.